Hôpital de la Timone

Running trials

• Not yet recruiting

  Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary Angioplasty

  NCT07644377· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Not yet recruiting

  An Optimization Study Evaluating Safety and Efficacy of the Y-90 Glioblastoma (GBM) Device in Patients With Recurrent GBM

  NCT07867886· Boston Scientific Corporation· Source

• Not yet recruiting

  Phase I/II trial of Dinutuximab beta in combination with Irinotecan and Rapamycin in pediatric, adolescents and adult patients with relapsed/refractory bone tumors. BONE DINIRRA

  2026-525463-40-00· Phase 1/2· Les Hopitaux Universitaires De Strasbourg· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Charite University, Berlin, Germany· Source

• Not yet recruiting

  Evaluation of the FYNA Research OPM MEG Device for Locating Epileptic Foci as Part of Pre-surgical Assessment of Epilepsy

  NCT07281222· Hospices Civils de Lyon· Source

• Recruiting

  Lidocaine for opioid sparing in vaso-occlusive crisis of Sickle Cell Disease

  2024-518437-28-00· Phase 3· Centre Hospitalier Universitaire De Nantes· Source

• Not yet recruiting

  PRIMUS : Real World Usage for Real World Evidence of CDSS Use in Multiple Sclerosis

  NCT07647952· Nantes University Hospital· Source

• Not yet recruiting

  Intravenous Thrombolysis With Tenecteplase Plus Thrombectomy Versus Thrombectomy Alone In Patients With A Large Ischemic Stroke: A Multicenter Randomized Controlled Trial (IVT-ALL-IN)

  NCT07603440· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy_POG

  2025-523610-83-00· Phase 4· Institut Gustave Roussy· Source

• Recruiting

  BIO|STREAM.CSP Study

  NCT07393009· Biotronik SE & Co. KG· Source

• Recruiting

  A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06769698· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  Assessment of the Clinical and Economic Impact of Sim&Size, a Simulation Software for Implantable Devices Used in the Treatment of Intracranial Aneurysms: A Prospective Multicenter Study.

  NCT07433075· Sim&Cure· Source

• Recruiting

  Neo-adjuvant Immunotherapy in Patients With Localized Melanoma

  NCT07230613· Phase 2· UNICANCER· Source

• Recruiting

  LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.

  NCT07202897· Phase 3· Rennes University Hospital· Source

• Recruiting

  Multicentre Real-life Follow-up Study of Rare Epileptic Syndromes in Children and Adolescents

  NCT05126914· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

  NCT06948448· Phase 2· Ono Pharmaceutical Co., Ltd.· Source

• Recruiting

  Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors

  NCT07243470· Phase 1/2· Centre Leon Berard· Source

• Recruiting

  Irradiation in Paediatrics: Neurocognition, Neuroimaging and Evaluation of Memory and Attention

  NCT06599879· Institut Claudius Regaud· Source

• Recruiting

  Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

  NCT07407465· Phase 2· Gruppo Oncologico del Nord-Ovest· Source

• Active, not recruiting

  IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

  NCT06790706· Phase 2· Hospices Civils de Lyon· Source

• Not yet recruiting

  Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer

  NCT06999512· Phase 2/3· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Exelixis· Source

• Recruiting

  Prenatal Maternal Mental Health and Neurodevelopment in Congenital Heart Disease

  NCT06711666· Institut National de la Santé Et de la Recherche Médicale, France· Source

• Active, not recruiting

  A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

  NCT06872125· Phase 3· Stoke Therapeutics, Inc· Source

• Recruiting

  A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

  NCT06976268· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Recruiting

  Ruxolitinib Treatment in Inclusion Body Myositis

  NCT06536166· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour

  NCT06876532· Institut Claudius Regaud· Source

• Enrolling by invitation

  A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

  NCT06908226· Phase 3· Longboard Pharmaceuticals· Source

• Recruiting

  PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial

  2024-510772-20-00· Phase 2· Centre Hospitalier Universitaire De Dijon· Source

• Recruiting

  Transcriptomic Analysis to Put an End to Misdiagnosis in Patients With Rare Muscle Diseases

  NCT06833489· Assistance Publique Hopitaux De Marseille· Source

• Recruiting

  Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD

  NCT03593317· Phase 2· Hospices Civils de Lyon· Source

• Recruiting

  Efficacy of Personnalized Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epileptic

  NCT06334952· Assistance Publique Hopitaux De Marseille· Source

• Active, not recruiting

  Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting

  NCT06639620· AbbVie· Source

• Active, not recruiting

  A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

  NCT06719141· Phase 3· Longboard Pharmaceuticals· Source

• Active, not recruiting

  A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

  NCT06660394· Phase 3· Longboard Pharmaceuticals· Source

• Active, not recruiting

  Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

  NCT06333951· Phase 1· Amgen· Source

• Recruiting

  French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis

  NCT06147843· University Hospital, Limoges· Source

• Recruiting

  Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

  NCT06567015· Phase 1/2· Pierre Fabre Medicament· Source

• Recruiting

  Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

  NCT06476184· Phase 3· ARCAGY/ GINECO GROUP· Source

• Recruiting

  Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

  NCT06333314· Phase 2· UNICANCER· Source

• Recruiting

  POP-UP: a Single-arm, Two-cohort Study: an 8-week Trimodal Pre-habilitation Program for Patients With Pancreatic Ductal Adenocarcinoma and Oesogastric

  NCT06275737· GERCOR - Multidisciplinary Oncology Cooperative Group· Source

• Recruiting

  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  NCT06112314· Phase 3· Immunocore Ltd· Source

• Active, not recruiting

  A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

  NCT06402838· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

  NCT06253611· Phase 2· GERCOR - Multidisciplinary Oncology Cooperative Group· Source

• Recruiting

  Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA

  NCT06207981· Phase 3· Federation Francophone de Cancerologie Digestive· Source

• Active, not recruiting

  Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

  NCT06088290· Phase 3· PharmaMar· Source

• Recruiting

  A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

  NCT05639413· UNICANCER· Source

• Active, not recruiting

  ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach

  NCT05928416· ZIWIG· Source

• Recruiting

  PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years

  NCT05387954· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

Showing 50 of 109.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers13 recruiting
• Colorectal cancer8 recruiting
• Sarcoma7 recruiting
• Epilepsy5 recruiting
• Pancreatic cancer4 recruiting
• Head and neck cancer3 recruiting
• Heart failure3 recruiting
• Lung cancer3 recruiting
• Melanoma3 recruiting
• Neuroendocrine tumours3 recruiting
• Duchenne muscular dystrophy2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Kidney cancer2 recruiting
• Ovarian cancer2 recruiting
• Parkinson disease2 recruiting
• Stroke2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Amyloidosis1 recruiting
• Aplastic anaemia1 recruiting
• Brain aneurysm1 recruiting
• Chronic kidney disease1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Congenital heart disease1 recruiting
• Crohn's disease1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Endometrial cancer1 recruiting
• Glioblastoma1 recruiting
• High blood pressure1 recruiting
• Huntington's disease1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Liver and biliary tract cancer1 recruiting
• Multiple sclerosis1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroblastoma1 recruiting
• Pompe disease1 recruiting
• Prostate cancer1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Sickle cell disease1 recruiting

Closed trials

• Completed

  ALS Phase II Study of NX210c

  NCT06365216· Phase 2· Axoltis Pharma· Source

• Completed

  A phase I of TG6050 in the treatment of patients with metastatic lung cancer

  NCT05788926· Phase 1· Transgene· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

  NCT05383170· Phase 1/2· Cytovation AS· Source

• Completed

  Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

  NCT05642208· Phase 4· Nantes University Hospital· Source

• Completed

  Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT

  NCT05524324· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Long-term Comparative Cerebrovascular Outcome After Transplantation vs Standard Care in Sickle Cell Anemia

  NCT05053932· Centre Hospitalier Intercommunal Creteil· Source

• Recruiting

  Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

  NCT05254171· Phase 2/3· Panbela Therapeutics, Inc.· Source

• Terminated

  A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

  NCT05256381· Phase 2· SOTIO Biotech AG· Source

• Completed

  A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)

  NCT05258071· Phase 2· Integrative Research Laboratories AB· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Completed

  Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease

  NCT05423522· Phase 2· Medesis Pharma SA· Source

• Completed

  Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

  NCT05217927· Phase 4· Pfizer· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

  NCT05116202· Phase 1/2· Hoffmann-La Roche· Source

• Terminated

  Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

  NCT04854499· Phase 2· Gilead Sciences· Source

• Completed

  A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

  NCT04822350· Pfizer· Source

• Active, not recruiting

  Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

  NCT04793958· Phase 3· Mirati Therapeutics Inc.· Source

• Completed

  A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT04901195· Phase 3· UCB Biopharma SRL· Source

• Completed

  Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

  NCT04732494· Phase 2· BeiGene· Source

• Completed

  Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

  NCT04739202· Phase 2· Hospices Civils de Lyon· Source

• Withdrawn

  Efficacy and Safety of Perampanel in Combination in Glioma-refractory Epilepsy

  NCT03636958· Assistance Publique Hopitaux De Marseille· Source

• Completed

  Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

  NCT04696055· Phase 2· Bayer· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· NovoCure Ltd.· Source

• Completed

  Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

  NCT03947216· Phase 2· University Hospital, Strasbourg, France· Source

• Completed

  Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global

  NCT04236609· Concept Medical Inc.· Source

• Terminated

  Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease

  NCT04217447· Phase 3· University Hospital, Brest· Source

• Completed

  CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

  NCT04136171· Phase 3· Ionis Pharmaceuticals, Inc.· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source

• Completed

  MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma

  NCT04216953· Phase 1/2· Centre Leon Berard· Source

• Completed

  A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

  NCT04199104· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic VOD in Children With Nephroblastoma or ALL

  NCT04168788· University Hospital, Angers· Source

• Completed

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)

  NCT03806452· Phase 2· Theravia· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

  NCT03709680· Phase 2· Pfizer· Source

• Completed

  FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel

  NCT03723967· Phase 2· Centre Leon Berard· Source

• Completed

  Phase II Study of Regorafenib as Maintenance Therapy

  NCT03793361· Phase 2· Centre Oscar Lambret· Source

• Completed

  Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

  NCT03898180· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

  NCT03820986· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis

  NCT03293069· Phase 2/3· University Hospital, Lille· Source

• Completed

  Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

  NCT03777657· Phase 3· BeiGene· Source

• Completed

  Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis

  NCT03401060· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  A Study of BAX 888 in Male Adults With Severe Hemophilia A

  NCT03370172· Phase 1/2· Baxalta now part of Shire· Source

• Completed

  Polytetrafluoroethylen (PTFE) Vascular Prostheses With Heparin Bonded Luminal Surfaces vs Crude ePTFE

  NCT03430076· Nantes University Hospital· Source

• Completed

  Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer

  NCT02820857· Phase 2· Hospices Civils de Lyon· Source

• Completed

  Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

  NCT03179436· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)

  NCT02864004· Phase 3· Rennes University Hospital· Source

• Completed

  Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

  NCT02902029· Phase 2· University Hospital, Essen· Source

• Completed

  Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

  NCT02676349· Phase 2· Institut de Cancérologie de Lorraine· Source

• Completed

  PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer

  NCT02359968· Phase 2· Centre Oscar Lambret· Source

• Completed

  Study of Predictive Factors of Progression of Motor Neurone Disease

  NCT02360891· University Hospital, Lille· Source

Showing 50 of 54.

Conditions

Diseases this institution publishes on or runs trials for.

• Epilepsy56 works · 10 trials
• Sarcoma21 works · 15 trials
• Myasthenia gravis7 works · 0 trials
• Dermatomyositis and polymyositis (myositis)5 works · 1 trial
• Charcot-Marie-Tooth disease3 works · 0 trials